JP2018512154A - キメラタンパク質 - Google Patents
キメラタンパク質 Download PDFInfo
- Publication number
- JP2018512154A JP2018512154A JP2017553230A JP2017553230A JP2018512154A JP 2018512154 A JP2018512154 A JP 2018512154A JP 2017553230 A JP2017553230 A JP 2017553230A JP 2017553230 A JP2017553230 A JP 2017553230A JP 2018512154 A JP2018512154 A JP 2018512154A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- subject
- fas
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 62
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 62
- 210000004027 cell Anatomy 0.000 claims abstract description 148
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 85
- 239000003446 ligand Substances 0.000 claims abstract description 72
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 52
- 102000035085 multipass transmembrane proteins Human genes 0.000 claims abstract description 18
- 108091005494 multipass transmembrane proteins Proteins 0.000 claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 201000011510 cancer Diseases 0.000 claims abstract description 8
- 229960004641 rituximab Drugs 0.000 claims description 81
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 72
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 72
- 229960002450 ofatumumab Drugs 0.000 claims description 55
- 230000027455 binding Effects 0.000 claims description 54
- 150000007523 nucleic acids Chemical group 0.000 claims description 46
- 239000013598 vector Substances 0.000 claims description 34
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 30
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 30
- 102000035160 transmembrane proteins Human genes 0.000 claims description 29
- 108091005703 transmembrane proteins Proteins 0.000 claims description 29
- 108091008874 T cell receptors Proteins 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 230000004913 activation Effects 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 25
- 210000000130 stem cell Anatomy 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 230000001988 toxicity Effects 0.000 claims description 19
- 231100000419 toxicity Toxicity 0.000 claims description 19
- 230000028993 immune response Effects 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 230000035772 mutation Effects 0.000 claims description 17
- 108020001756 ligand binding domains Proteins 0.000 claims description 15
- 230000006907 apoptotic process Effects 0.000 claims description 14
- 230000001575 pathological effect Effects 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 13
- 210000004698 lymphocyte Anatomy 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 210000004899 c-terminal region Anatomy 0.000 claims description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 10
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 9
- 208000024908 graft versus host disease Diseases 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 230000002463 transducing effect Effects 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 238000012546 transfer Methods 0.000 claims description 8
- 229950000815 veltuzumab Drugs 0.000 claims description 7
- 238000011161 development Methods 0.000 claims description 6
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 238000010361 transduction Methods 0.000 claims description 6
- 230000026683 transduction Effects 0.000 claims description 6
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010066817 Activation syndrome Diseases 0.000 claims description 4
- 230000005934 immune activation Effects 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 201000001268 lymphoproliferative syndrome Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000035515 penetration Effects 0.000 claims description 2
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 56
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 54
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 52
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 52
- 239000000427 antigen Substances 0.000 description 26
- 108091007433 antigens Proteins 0.000 description 25
- 102000036639 antigens Human genes 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 22
- 210000000822 natural killer cell Anatomy 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 16
- 230000002147 killing effect Effects 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 10
- 210000003289 regulatory T cell Anatomy 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 6
- 102000010170 Death domains Human genes 0.000 description 6
- 108050001718 Death domains Proteins 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 238000002659 cell therapy Methods 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 210000003071 memory t lymphocyte Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 229960003347 obinutuzumab Drugs 0.000 description 5
- 238000011476 stem cell transplantation Methods 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000004068 intracellular signaling Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 102000004091 Caspase-8 Human genes 0.000 description 3
- 108090000538 Caspase-8 Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 3
- 101150089023 FASLG gene Proteins 0.000 description 3
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 3
- 102000019298 Lipocalin Human genes 0.000 description 3
- 108050006654 Lipocalin Proteins 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000006274 endogenous ligand Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 210000004986 primary T-cell Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 108700012439 CA9 Proteins 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 101710165471 Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 2
- 108091006383 Type IV transmembrane proteins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000011467 adoptive cell therapy Methods 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 108010052621 fas Receptor Proteins 0.000 description 2
- 102000018823 fas Receptor Human genes 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 210000002768 hair cell Anatomy 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 210000002602 induced regulatory T cell Anatomy 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000009258 tissue cross reactivity Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101150027879 FOXP3 gene Proteins 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 101001027052 Homo sapiens Thymidylate kinase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 1
- 108010039918 Polylysine Chemical group 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 244000191761 Sida cordifolia Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004703 blastocyst inner cell mass Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 208000015322 bone marrow disease Diseases 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 210000004667 early pro-b cell Anatomy 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002202 late pro-b cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 108091005763 multidomain proteins Proteins 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940099990 ogen Drugs 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000656 polylysine Chemical group 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本発明は、養子細胞療法(ACT)に有用なキメラタンパク質に関する。キメラタンパク質は、自殺遺伝子として作用して、キメラタンパク質を発現する細胞を排除することを可能にし得る。本発明はまた、かかるキメラタンパク質をコードする核酸、かかる核酸を含む細胞、およびその治療的使用を提供する。
養子免疫療法は、確立された発展的治療手法である。同種異系造血幹細胞移植(HSCT)の状況では、血液悪性腫瘍の再発を処置するために、ドナーリンパ球注入(DLI)が頻繁に行われる。腫瘍浸潤リンパ球(TIL)は、転移性メラノーマの処置に有効である。T細胞の遺伝子操作は、T細胞療法の範囲および効力を大きく増加させる:T細胞受容体移入は、細胞内癌抗原の標的化を可能にする一方、キメラ抗原受容体(CAR)は、表面癌または系統特異的抗原の標的化を可能にする。臨床的応答は、両方の手法で観察されており、多数のさらなる試験が進行中である。
自殺遺伝子
したがって、上記欠点を伴わない代替的な自殺遺伝子が必要である。
・細胞のアポトーシスをもたらすFASエンドドメインの活性化;
・補体依存性細胞傷害(CDC)をもたらす複数のキメラタンパク質の複数回貫通型膜貫通タンパク質の架橋;および
・抗体依存性細胞媒介性細胞傷害(ADCC)(この場合、細胞外リガンドは、抗体である)
の1つ、2つまたは3つすべてを引き起こし得る。
(i)本発明の第3の態様によるベクターを、被験体から単離された細胞の試料に形質導入またはトランスフェクトする工程、および
(ii)前記形質導入/トランスフェクトされた細胞を患者に投与する工程
を含み得る。
(i)本発明の第4の態様による細胞を前記被験体に投与する工程;
(ii)病理学的免疫応答の発症について、前記被験体をモニタリングする工程;および
(iii)前記被験体が、病理学的免疫応答を発症するまたは発症した兆候を示す場合、複数回貫通型膜貫通タンパク質に結合することができる細胞外リガンドを前記被験体に投与する工程
を含み得る。
キメラタンパク質
本発明は、自殺遺伝子として作用するキメラタンパク質に関する。キメラタンパク質を発現する細胞は、細胞外リガンドの投与によって、インビボまたはインビトロで排除され得る。
配列番号1
複数回貫通型膜貫通タンパク質
CD20
配列番号3
配列番号4(dCD20)
配列番号5(CD20d)
配列番号6(dCD20P172W)
FASエンドドメイン
配列番号20
配列番号29
細胞外リガンド
CD20モノクローナル抗体
・非ホジキンリンパ腫および慢性リンパ球性白血病(CLL)の処置のためのリツキシマブ
・オファツムマブは、CLLについて、2009年10月にFDAによって承認された;
・オビヌツズマブは、CLLについて、2013年11月にFDAによって承認された;
リツキシマブ重鎖可変鎖配列(配列番号21)
オファツムマブ重鎖可変鎖配列(配列番号23)
核酸配列
配列番号25 dCD20−FAS
i)FASエンドドメインに融合された複数回貫通型膜貫通タンパク質を含むキメラタンパク質をコードする第1の核酸配列;および
ii)目的のヌクレオチド(NOI)をコードする第2の核酸配列
を含む核酸構築物を提供する。
配列番号27または28として示されている配列を有する口蹄疫ウイルス(FMDV)2a自己切断ペプチドを含む様々な自己切断部位が公知である:
配列番号27
配列番号28
T細胞受容体(TCR)
キメラ抗原受容体(CAR)
ベクター
細胞
ヒトでは、3つの公知の利用可能な自己成体幹細胞源がある:
1.採取による抽出(すなわち、骨穿孔)を必要とする骨髄。
2.脂肪吸引による抽出を必要とする脂肪組織。
3.アフェレーシス(血液をドナーから採血し、幹細胞を抽出して血液の他の部分をドナーに戻す機械に通す)による抽出を必要とする血液。
(i)被験体または上記で挙げた他の供給源からのTまたはNK細胞含有試料の単離;および
(ii)本発明の第2の態様による1つまたはそれより多くの核酸配列(複数も可)によるTまたはNK細胞の形質導入またはトランスフェクション
により作製され得る。
医薬組成物
方法
(i)本発明の第3の態様によるベクターを、被験体から単離された細胞の試料に形質導入またはトランスフェクトする工程、および
(ii)前記形質導入/トランスフェクトした細胞を患者に投与する工程
を含み得る。
(i)本発明の第4の態様による細胞を前記被験体に投与する工程;
(ii)病理学的免疫応答の発症について、前記被験体をモニタリングする工程;および
(iii)前記被験体が、病理学的免疫応答を発症するまたは発症した兆候を示す場合、ラパマイシンまたはラパマイシン類似体を前記被験体に投与する工程
を含む方法を提供する。
実施例1−先端切除バージョンのCD20の試験
実施例2−低い基本毒性を有するFASキメラの生産
実施例3−リツキシマブに対する感度の調査
実施例4−オファツムマブに対する感度の調査
実施例5−オファツムマブ結合ではなくリツキシマブ結合を破壊するためのCD20の操作
実施例6−ADCCの研究
実施例7−初代ヒトT細胞におけるdCD20−FASおよびdCD20P172W−FASの機能の研究
Claims (29)
- FASエンドドメインに融合された複数回貫通型膜貫通タンパク質を含むキメラタンパク質であって、前記複数回貫通型膜貫通タンパク質が細胞外リガンドに結合して、前記FASエンドドメインの活性化をもたらす、キメラタンパク質。
- 前記複数回貫通型膜貫通タンパク質が、CD20、またはアミノ末端エンドドメインもしくはカルボキシ末端エンドドメインを欠くその先端切除バージョンである、請求項1に記載のキメラタンパク質。
- 前記細胞外リガンドが、リツキシマブ、オファツムマブまたはベルツズマブである、請求項2に記載のキメラタンパク質。
- 前記アミノ末端エンドドメインを欠く先端切除バージョンのCD20のカルボキシ末端に融合されたFASエンドドメインを含む、請求項2に記載のキメラタンパク質。
- 前記CD20が、配列番号3として示されている全長配列を基準にして、突然変異P172Wを含む、請求項2に記載のキメラタンパク質。
- 前記CD20が、配列番号3、4、5または6として示されている配列を含む、請求項2に記載のキメラタンパク質。
- 前記複数回貫通型膜貫通タンパク質が、前記細胞外リガンドに結合する異種リガンド結合ドメインを含む、請求項1に記載のキメラタンパク質。
- 前記FASエンドドメインが、配列番号20として示されている配列を含む、先行する請求項のいずれかに記載のキメラタンパク質。
- 先行する請求項のいずれかに記載のキメラタンパク質をコードする、核酸配列。
- 1つまたはそれより多い請求項9に記載の核酸配列と、T細胞受容体(TCR)またはキメラ抗原受容体(CAR)をコードする核酸配列とを含む、核酸構築物。
- 請求項9に記載の核酸配列または請求項10に記載の核酸構築物を含む、ベクター。
- 目的のヌクレオチドも含む、請求項9に記載の核酸配列を含む、ベクター。
- 前記ベクターを標的細胞の形質導入に使用する場合、前記標的細胞が、請求項1〜8のいずれかに記載のキメラタンパク質およびキメラ抗原受容体またはT細胞受容体を共発現するように、前記目的のヌクレオチドがキメラ抗原受容体またはT細胞受容体をコードする、請求項12に記載のベクター。
- 請求項1〜8のいずれかに記載のキメラタンパク質を発現する、細胞。
- T細胞、ナチュラルキラー(NK)細胞または幹細胞である、請求項14に記載の細胞。
- 請求項14または15に記載の細胞を作製するための方法であって、請求項11〜13のいずれかに記載のベクターを細胞に形質導入またはトランスフェクトする工程を含む、方法。
- 請求項14または15に記載の細胞を排除するための方法であって、前記複数回貫通型膜貫通タンパク質に結合する細胞外リガンドに前記細胞を曝露する工程を含む、方法。
- 前記細胞外リガンドの結合が、前記FASエンドドメインの活性化および前記細胞のアポトーシスをもたらす、請求項17に記載の方法。
- 前記細胞外リガンドの結合が、複数のキメラタンパク質の複数回貫通型膜貫通タンパク質の架橋をもたらして、補体依存性細胞傷害(CDC)をもたらす、請求項17に記載の方法。
- 前記細胞外リガンドが抗体であり、前記細胞外リガンドの結合が、抗体依存性細胞媒介性細胞傷害(ADCC)をもたらす、請求項17に記載の方法。
- 前記細胞外リガンドが、リツキシマブ、オファツムマブまたはベルツズマブである、請求項17〜20のいずれかに記載の方法。
- 被験体における疾患を予防または処置するための方法であって、請求項14または15に記載の細胞を前記被験体に投与する工程を含む、方法。
- 以下:
(i)請求項11〜13のいずれかに記載のベクターを、被験体から単離された細胞の試料に形質導入またはトランスフェクトする工程、および
(ii)前記形質導入/トランスフェクトされた細胞を患者に投与する工程
を含む、請求項22に記載の方法。 - 癌を処置するための、請求項23に記載の方法。
- 被験体への請求項14または15に記載の細胞の投与によって引き起こされる、前記被験体における病理学的免疫応答を予防および/または処置するための方法であって、前記複数回貫通型膜貫通タンパク質に結合することができる細胞外リガンドを前記被験体に投与する工程を含む、方法。
- 前記病理学的免疫応答が、以下の群:移植片対宿主病;オンターゲットオフ腫瘍毒性;免疫活性化症候群;およびリンパ増殖性障害から選択される、請求項25に記載の方法。
- 請求項22に記載の、被験体における疾患を処置するための方法であって、以下:
(i)請求項14または15に記載の細胞を前記被験体に投与する工程;
(ii)病理学的免疫応答の発症について、前記被験体をモニタリングする工程;および
(iii)前記被験体が、病理学的免疫応答を発症するまたは発症した兆候を示す場合、前記複数回貫通型膜貫通タンパク質に結合することができる細胞外リガンドを前記被験体に投与する工程
を含む、方法。 - 造血幹細胞移植、リンパ球注入または養子細胞移入に使用するための、請求項14または15に記載の細胞。
- 被験体への請求項14または15に記載の細胞の投与によって引き起こされる病理学的免疫応答の予防または処置に使用するための、抗CD20抗体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1506223.5A GB201506223D0 (en) | 2015-04-13 | 2015-04-13 | Chimeric protein |
GB1506223.5 | 2015-04-13 | ||
PCT/GB2016/051019 WO2016166521A1 (en) | 2015-04-13 | 2016-04-12 | Chimeric protein |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018512154A true JP2018512154A (ja) | 2018-05-17 |
JP2018512154A5 JP2018512154A5 (ja) | 2019-02-28 |
JP6704411B2 JP6704411B2 (ja) | 2020-06-03 |
Family
ID=53333686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017553230A Expired - Fee Related JP6704411B2 (ja) | 2015-04-13 | 2016-04-12 | キメラタンパク質 |
Country Status (10)
Country | Link |
---|---|
US (1) | US10869911B2 (ja) |
EP (1) | EP3283526B1 (ja) |
JP (1) | JP6704411B2 (ja) |
CN (1) | CN107531804A (ja) |
AU (1) | AU2016250200B2 (ja) |
CA (1) | CA2981846A1 (ja) |
ES (1) | ES2749903T3 (ja) |
GB (1) | GB201506223D0 (ja) |
HK (1) | HK1243107B (ja) |
WO (1) | WO2016166521A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022514354A (ja) * | 2018-12-20 | 2022-02-10 | ザ・ユニバーシティ・オブ・シカゴ | がん治療のための治療用ペプチドに関する方法および組成物 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201519900D0 (en) * | 2015-11-11 | 2015-12-23 | Ucl Business Plc | Chimeric antigen receptor |
CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技(香港)有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
GB201716728D0 (en) | 2017-10-12 | 2017-11-29 | Autolus Ltd | Cell |
JP2023502520A (ja) * | 2019-11-21 | 2023-01-24 | リミディアム バイオ,インコーポレーテッド | 増殖因子の回復 |
WO2024117920A1 (en) * | 2022-11-29 | 2024-06-06 | Malcorp Biodiscoveries Limited | Novel cd20 protein |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9914650D0 (en) * | 1999-06-24 | 1999-08-25 | Angyogene Pharmaceuticals Ltd | Chimeric proteins mediating targeted apoptosis |
US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
PT2496698T (pt) * | 2009-11-03 | 2019-04-18 | Hope City | Recetor de fator de crescimento epidermal truncado (egfrt) para seleção de células t transduzidas |
US10590202B2 (en) | 2012-11-19 | 2020-03-17 | Baliopharm Ag | Recombinant bispecific antibody binding to CD20 and CD95 |
JP2017100947A (ja) * | 2014-03-31 | 2017-06-08 | 株式会社オーダーメードメディカルリサーチ | 目的抗原に対する抗体の作製方法 |
-
2015
- 2015-04-13 GB GBGB1506223.5A patent/GB201506223D0/en not_active Ceased
-
2016
- 2016-04-12 EP EP16717433.3A patent/EP3283526B1/en active Active
- 2016-04-12 CA CA2981846A patent/CA2981846A1/en not_active Abandoned
- 2016-04-12 CN CN201680021442.1A patent/CN107531804A/zh active Pending
- 2016-04-12 US US15/565,914 patent/US10869911B2/en active Active
- 2016-04-12 ES ES16717433T patent/ES2749903T3/es active Active
- 2016-04-12 AU AU2016250200A patent/AU2016250200B2/en not_active Ceased
- 2016-04-12 JP JP2017553230A patent/JP6704411B2/ja not_active Expired - Fee Related
- 2016-04-12 WO PCT/GB2016/051019 patent/WO2016166521A1/en active Application Filing
-
2018
- 2018-02-26 HK HK18102740.9A patent/HK1243107B/zh unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022514354A (ja) * | 2018-12-20 | 2022-02-10 | ザ・ユニバーシティ・オブ・シカゴ | がん治療のための治療用ペプチドに関する方法および組成物 |
Also Published As
Publication number | Publication date |
---|---|
CA2981846A1 (en) | 2016-10-20 |
EP3283526B1 (en) | 2019-09-04 |
US20180169189A1 (en) | 2018-06-21 |
WO2016166521A1 (en) | 2016-10-20 |
AU2016250200B2 (en) | 2020-08-13 |
CN107531804A (zh) | 2018-01-02 |
GB201506223D0 (en) | 2015-05-27 |
ES2749903T3 (es) | 2020-03-24 |
EP3283526A1 (en) | 2018-02-21 |
JP6704411B2 (ja) | 2020-06-03 |
HK1243107B (zh) | 2020-05-08 |
US10869911B2 (en) | 2020-12-22 |
AU2016250200A1 (en) | 2017-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10478457B2 (en) | Chimeric protein | |
TWI840351B (zh) | T細胞受體及表現其之工程化細胞 | |
AU2019225798B2 (en) | Nyeso tcr | |
JP2022058681A (ja) | 受容体 | |
JP6704411B2 (ja) | キメラタンパク質 | |
CN109476722A (zh) | 用于改善免疫细胞的功效和扩张的方法 | |
JP2017537622A (ja) | がんを治療するための方法及び組成物 | |
EP3833682B1 (en) | Suicide module compositions and methods | |
KR20220007675A (ko) | 아세틸콜린 수용체 키메라 자가항체 수용체 세포의 조성물 및 방법 | |
TWI843716B (zh) | hTERT特異性結合分子 | |
CN115516086A (zh) | 类猿icp47及变体减少同种异体细胞宿主排斥的组合物及方法 | |
WO2017004579A1 (en) | Artificial antigen presenting cells for adoptive cell therapy against cancer | |
TW202346576A (zh) | 治療性t細胞產品 | |
CN117616116A (zh) | 突变体il-15组合物及其方法 | |
JP2020508642A (ja) | 耐性を誘導するための操作された細胞 | |
NZ735850B2 (en) | Claudin-18.2-specific immunoreceptors and t cell epitopes | |
NZ723544B2 (en) | Claudin-6-specific immunoreceptors and t cell epitopes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190118 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190118 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191024 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191226 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200508 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200512 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6704411 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |